Kevin Fielding
President @ Parthus
Kevin Fielding is a funding round investor at Parthus focused on Medical and Chemical. Core expertise: building and managing companies in the semiconductor industry. Interested in companies doing product development for mobile computing, wireless communications and consumer entertainment applications.Career: President and CEO, ParthusCeva (Nasdaq: CEVA); President, Parthus Technologies plc (IPO 2000); founder and MD, theStrongARM microprocessor business (acquired by Intel 1998); DEC (original Alpha processor); Philips BV (high-speed processor design); National Microelectronics Research Centre, Cork.Academic achievements: MBA, Northeastern University, Boston; Masters and BE degrees in Electrical Engineering, University of Ireland, Cork.
- Total investments:
- 1
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Kevin Fielding invests in
Stages Kevin Fielding invests in
Countries Kevin Fielding invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Medical 1 (100%)
- Chemical 1 (100%)
- Pharmaceutical 1 (100%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Solvotrin Therapeutics
|
Solvotrin Therapeutics Limited is a privately held pharmaceutical company focused on cardiovascular applications.Solvotrin’s business model is based on the development of new drugs that combine its unique patented prodrug platform with well established compounds in large markets. Its approach of chemically creating new chemical entities fromexisting compounds for synergistic benefits creates efficacy and safety advantages with significantly reduced development timeline and development risk.Solvotrin’s lead compound, ST0702 is a nicotinic acid prodrug, with significant efficacy and tolerability advantages over similar products for 54 dyslipidaemia. ST0701 is a bioactivated form of aspirin, which addresses the well documented gastrointestinal toxicity of aspirin. ST0703 is a ’nitro-aspirin‘ prodrug with dual antiplatelet effects and disease modifying potential.The company has a strong intellectual property underpin with patent protection at the highest, New Molecule level. Solvotrin’s strategy is to take its compounds to the end of Phase I and to partner the development and commercialisation phases with large pharmaceutical companies. | $2.1M / Feb 10, 2017 |
Co-Investors
About Parthus
Parthus.
Parthus Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Kevin Fielding
President
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Kevin Fielding invest in?
Kevin Fielding invests primarily in Medical, Chemical and Pharmaceutical startups, most often at Funding Round stage. Most of the 1 investments tracked by Shizune back companies in Ireland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Kevin Fielding?
Public channels for Kevin Fielding include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Kevin Fielding last invest?
The most recent investment recorded for Kevin Fielding closed in Feb 2017. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
